Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;24(3):1800698.
doi: 10.2807/1560-7917.ES.2019.24.3.1800698.

Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018

Emi Takashita  1 , Chiharu Kawakami  2 , Hiroko Morita  1 , Rie Ogawa  1 , Seiichiro Fujisaki  1 , Masayuki Shirakura  1 , Hideka Miura  1 , Kazuya Nakamura  1 , Noriko Kishida  1 , Tomoko Kuwahara  1 , Keiko Mitamura  3 , Takashi Abe  4 , Masataka Ichikawa  5 , Masahiko Yamazaki  6 , Shinji Watanabe  1 , Takato Odagiri  1 ; Influenza Virus Surveillance Group of Japan  7
Affiliations

Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018

Emi Takashita et al. Euro Surveill. 2019 Jan.

Abstract

The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir.

Keywords: Influenza virus; baloxavir acid; baloxavir marboxil; cap-dependent endonuclease inhibitor; resistant.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure
Figure
Detection of influenza viruses, Japan, September 2015–December 2018 (n = 28,093)
See this image and copyright information in PMC

References

    1. Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses. 2017;11(3):240-6. 10.1111/irv.12446 - DOI - PMC - PubMed
    1. Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-23. 10.1056/NEJMoa1716197 - DOI - PubMed
    1. Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8(1):9633. 10.1038/s41598-018-27890-4 - DOI - PMC - PubMed
    1. Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, et al. Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Front Microbiol. 2018;9(3026):3026. 10.3389/fmicb.2018.03026 - DOI - PMC - PubMed
    1. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther. 2007;12(4 Pt B):603-16. - PubMed

MeSH terms